KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Shares Outstanding (Weighted Average) (2016 - 2025)

Sarepta Therapeutics has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $100.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 5.31% year-over-year to $100.1 million; the TTM value through Dec 2025 reached $100.1 million, up 5.31%, while the annual FY2025 figure was $100.1 million, 5.31% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $100.1 million at Sarepta Therapeutics, up from $98.5 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $100.1 million in Q4 2025 and troughed at $79454.0 in Q1 2021.
  • A 5-year average of $82.0 million and a median of $88.8 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): tumbled 99.9% in 2021 and later skyrocketed 109715.74% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $81.3 million in 2021, then grew by 7.75% to $87.6 million in 2022, then increased by 5.53% to $92.4 million in 2023, then rose by 2.9% to $95.1 million in 2024, then rose by 5.31% to $100.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SRPT at $100.1 million in Q4 2025, $98.5 million in Q3 2025, and $97.7 million in Q2 2025.